{
  "ticker": "IRX",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02971876",
  "id": "02971876",
  "pages": 20,
  "price_sensitive": false,
  "date": "20250723",
  "time": "1154",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250723/pdf/06m20tt9phk027.pdf",
  "summary": "**Summary of InhaleRx ASX Announcement (Presentation):**  \n\n**Key Highlights:**  \n- **Pipeline Development:**  \n  - **IRX-211 (Breakthrough Cancer Pain):**  \n    - Phase 1 trial complete; no SAEs reported.  \n    - Phase 2 trial milestones: HREC approval secured, manufacturing commenced; first patient dosing expected Q3 2025.  \n    - Global cancer pain market projected to reach **$11.23B by 2030 (6.09% CAGR)**.  \n  - **IRX-616a (Panic Disorder):**  \n    - Phase 1 HREC submission pending; Phase 2 to follow.  \n    - **$22.6B (USD)** anxiety/depression treatment market; no FDA-approved inhaled competitors.  \n\n- **Funding & Financials:**  \n  - **$38.5M facility secured** for clinical development.  \n  - Reduced cash burn; lean management team.  \n\n- **Regulatory:**  \n  - FDA pathway validated via PIND meetings (IRX-211).  \n\n**Material Catalysts:**  \n- IRX-211 Phase 2 first patient dose (Q3 2025).  \n- IRX-616a Phase 1 HREC approval (Q3 2025).  \n\n**No capital raising, operational, or liquidity changes disclosed.**  \n\n---  \n*Note: Presentation contains forward-looking statements; no new material financial data (e.g., cash balance) provided.*",
  "usage": {
    "prompt_tokens": 2544,
    "completion_tokens": 309,
    "total_tokens": 2853,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-23T03:25:14.993172"
}